Second, due to the strict reimbursement criteria (Table 4) of the National Health Insurance, not all patients with indications of AMD/PCV, DME, RVO or myopic CNV were eligible to receive anti-VEGF treatment. This evidence concerns the gene VEGFA and age-related macular degeneration.